<div id="readability-page-1">New insider activity at Abbott Laboratories ( (ABT) ) has taken place on January 26, 2026.<h3>Claim 50% Off TipRanks Premium</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential</li></ul> Chairman and CEO Robert Ford has made a significant show of confidence in Abbott Laboratories by purchasing 18,800 shares of the company’s stock, in a transaction valued at $2,013,856. Recent Updates on ABT stock In the last 24 hours, Abbott Laboratories’ stock action has been driven mainly by reactions to its Q4 earnings call and 2026 outlook rather than any single headline move in price. Investors focused on the company’s reaffirmed expectation of high-single-digit organic sales growth and roughly 10% EPS expansion, underpinned by strong performance and margin gains in medical devices, diagnostics, and the continuous glucose monitoring (CGM) franchise. Any changes in analyst price targets referenced in the news flow are primarily linked to this mix of positives and offsets: on the positive side, double-digit EPS growth, expanding gross and operating margins from cost discipline and a shift toward higher-margin businesses, robust growth in devices and CGM, an active innovation pipeline with multiple new product launches, and the strategic acquisition of Exact Sciences to create a new high-growth cancer diagnostics vertical. On the more cautious side, analysts are factoring in weaker near-term prospects for the Nutrition segment due to lost U.S. pediatric market share, the impact of losing a major WIC contract, and demand pressure after prior price hikes, as well as ongoing structural headwinds from declining COVID testing revenues and pricing pressures in China tied to volume-based procurement. The interplay of these factors—strong core businesses and pipeline versus softer Nutrition and external diagnostic headwinds—explains the rationale behind recent revisions to forward expectations and associated price targets, even as the overall medium-term outlook remains one of steady growth and margin expansion. Spark’s Take on ABT Stock According to Spark, TipRanks’ AI Analyst, ABT is a Outperform. The score is driven primarily by strong underlying financial performance and constructive 2026 guidance with continued Devices/CGM strength and margin expansion. This is partially offset by very weak technical momentum (price below major moving averages with oversold indicators) and a premium valuation (P/E ~32) that reduces upside support. To see Spark’s full report on ABT stock, click here. More about Abbott Laboratories YTD Price Performance: -13.83% Average Trading Volume: 7,138,963 Technical Sentiment Signal: Sell Current Market Cap: $186.8B</div>

Abbott Laboratories' CEO Robert Ford purchased 18,800 shares worth $2,013,856, signaling confidence in the company. The stock's recent performance is influenced by Q4 earnings and a positive 2026 outlook, with expectations of high-single-digit organic sales growth and 10% EPS expansion. Analysts note strong growth in medical devices and diagnostics, but caution over weaker prospects in the Nutrition segment and external pressures. TipRanks' AI Analyst rates ABT as Outperform, citing strong financial performance despite technical weaknesses and a high valuation. Year-to-date, ABT's price has dropped by 13.83%.

Tip Ranks

SPDR S&P Health Equip

Health Care Select Sector SPDR

iShares US Medical Devices

Top Executive Makes Bold Move With Major Abbott Laboratories Stock Purchase